Back to Search
Start Over
Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models.
- Source :
-
Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Jan; Vol. 11 (1). - Publication Year :
- 2023
-
Abstract
- Background: Anti-PD-1 immune checkpoint blockade is approved for first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but few patients respond. Statin drugs (HMG-CoA reductase inhibitors) are associated with superior survival in several cancer types, including HNSCC. Emerging data suggest that manipulation of cholesterol may enhance some aspects of antitumor immunity.<br />Methods: We used syngeneic murine models (mouse oral cancer, MOC1 and TC-1) to investigate our hypothesis that a subset of statin drugs would enhance antitumor immunity and delay tumor growth.<br />Results: Using an ex vivo coculture assay of murine cancer cells and tumor infiltrating lymphocytes, we discovered that all seven statin drugs inhibited tumor cell proliferation. Simvastatin and lovastatin also enhanced T-cell killing of tumor cells. In mice, daily oral simvastatin or lovastatin enhanced tumor control and extended survival when combined with PD-1 blockade, with rejection of MOC1 tumors in 30% of mice treated with lovastatin plus anti-PD-1. Results from flow cytometry of tumors and tumor-draining lymph nodes suggested T cell activation and shifts from M2 to M1 macrophage predominance as potential mechanisms of combination therapy.<br />Conclusions: These results suggest that statins deserve further study as well-tolerated, inexpensive drugs that may enhance responses to PD-1 checkpoint blockade and other immunotherapies for HNSCC.<br />Competing Interests: Competing interests: NCS: Consulting: Checkpoint Surgical, Sensorion Book Royalties: Plural Publishing Clinical Trial Funding: Astex Pharmaceuticals CP—Research funding through a sponsored research agreement between the Medical University of South Carolina and Obsidian, Lycera, ThermoFisher and is the Co-Founder of Ares Immunotherapy GBL—Grant/Research Support through sponsored research agreements between Emory University and from Merck and Co., Bristol-Myers Squibb, Boerhinger-Ingelheim and Vaccinex and a consulting or advisory role for ProDa Biotech.<br /> (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Subjects :
- Animals
Mice
Squamous Cell Carcinoma of Head and Neck drug therapy
Immune Checkpoint Inhibitors
Lovastatin pharmacology
Lovastatin therapeutic use
Simvastatin pharmacology
Simvastatin therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Head and Neck Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2051-1426
- Volume :
- 11
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal for immunotherapy of cancer
- Publication Type :
- Academic Journal
- Accession number :
- 36650022
- Full Text :
- https://doi.org/10.1136/jitc-2022-005940